Lonza has completed the carve-out of its Specialty Ingredients business as LSI and appointed a management team led by CEO Mark Doyle, a former DuPont and DowDuPont chief...

Lonza is investing 20 million Swiss francs in an expansion of its API development and manufacturing facility at Nansha, China. The Basel-based CDMO said the expanded...

Swiss CDMO Lonza is collaborating with Swedish pharma SelectImmune to develop processes for NlpD, a novel immunotherapy protein that could provide an alternative to...

As it ramps up production on three continents, US Covid-19 vaccine manufacturer Moderna is expanding its collaborations with CDMO suppliers in Europe, the US and Asia. At...

In two major new investments at its sites in Visp, Switzerland, and Portsmouth New Hampshire, USA, Swiss CDMO Lonza said it will spend 850 million Swiss francs to expand...

Swiss CDMO Lonza and US vaccine maker Moderna have extended and deepened their collaboration on the US biotech’s mRNA- based Covid-19 shot. The new agreement, which calls...

Swiss CDMO Lonza is investing 200 million Swiss francs at its Alpine site in Visp to build a new manufacturing complex for a long-term biopharmaceutical manufacturing...

Swiss CDMO Lonza and China pharma Junshi Biosciences have expanded their biologics collaboration. Lonza will leverage its global network and local operation capabilities...